Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Approved Product and Revenue Stream: Rigel has an approved commercial product, TAVALISSE (fostamatinib), generating revenue from its use in chronic immune thrombocytopenia (ITP), providing financial stability and market presence.
Differentiated Mechanism of Action: Fostamatinib offers a unique mechanism of action, targeting spleen tyrosine kinase (SYK), providing an important alternative for ITP patients who have failed other treatment options.
Specialized Market Focus: The company concentrates on developing therapies for severe immune and hematologic disorders, allowing for deep expertise and a more targeted approach to addressing unmet medical needs in specific patient populations.
Risks
Clinical Trial Failures: The success of RIGL's pipeline depends on successful clinical development, and any setbacks or failures in ongoing or future trials could halt development and diminish its value.
Regulatory Approval Hurdles: RIGL faces significant uncertainty in obtaining and maintaining regulatory approvals for its drug candidates from agencies like the FDA, a process that is lengthy, expensive, and not guaranteed.
Funding and Liquidity Concerns: RIGL has a history of operating losses and may require substantial additional capital to fund its operations, research, and commercialization efforts, potentially leading to dilution for existing shareholders.
Over a week ago
May 27, 10:34 AM
May 27, 10:30 AM
May 13, 5:50 AM
May 7, 6:41 AM
May 5, 4:04 PM
May 5, 4:02 PM
Mar 31, 8:10 AM
Mar 3, 4:06 PM
Mar 3, 4:04 PM
Jan 14, 5:42 AM
Jan 12, 8:09 AM
Jan 12, 8:07 AM
Dec 7, 12:49 PM
Nov 17, 8:13 AM
Nov 5, 3:50 PM
Nov 5, 3:47 PM
Nov 5, 8:32 AM